“I think net-net, I don't expect any step changes in GLP pricing as a result of Montero launching but it is part of the national pressure intention and contract negotiations.”

In context

“e Manzaro launch. What are your expectations here going forward? Is it a trend is higher rebates and negative channel mix noted by your competitor on the eosyesterday. So interested to get in the meal perspective here? And then a quick question for Anat. When do you anticipate having greater clarity on the possible repeal in the 2017 tax… Kevin Hern: Great. Thanks, Gary. We'll go to Mike for the question on anchored and market price trends and then not for the question on tax reform... Kerry Holford: Mike? Mike Mason: Yes. That's a good question. I think naturally, payers will ask for additional rebates when a new product joins a formulary. So as part of our discussion of being disciplined and why you don't want to accelerate those discussions too rapidly and that's a factor into it. So I think net-net, I don't expect any step changes in GLP pricing as a result of Montero launching but it is part of the national pressure intention and contract negotiations. Kerry Holford: Thanks, Mike. Anat? Anat Ashkenazi: So on taxes, what we are seeing is we're seeing broad bipartisan support for appealing that change of capitalizing R&D expenses. -- was evident in the recent Senate letter. This could come. We believe it will come through by the end of this year, most likely if I had to guess, I would say, towards the end of the year, potentially as part of a tech tender. Kerry Holford: Thanks, Anat. Operator: The next call is Mohit Bansal from Wells Fargo. Dave Ricks: Maybe one question on the SELECT-EARLY study, the diabetic study. So maybe one for you, Dan. What you really need to show how long the trial and what you need to show in terms of delta versus control to be -- to prove that it is beneficial in prediabetic patients. And wouldn't oral JLP a”